ZEO ScientifiX Inc (OTCQB: ZEOX) is a biotech company that develops, processes, and distributes biologically derived products from perinatal tissue material, marketed under the Organicell brand. Revenue is generated through the sale and distribution of these products, with the company also having entered a sales representative agreement with Exotropin LLC for skin care products as of August 2024 and acquiring topical aesthetic products through its June 2025 purchase of BioLumina LLC. The company trades on the OTCQB tier of the OTC Markets Group, operates with limited assets and a limited history of successful operations, and depends on external capital to fund operations, as disclosed in its 10-K filed January 29, 2026. Leadership as of that filing includes Ian T. Bothwell as Chief Executive Officer, Chief Financial Officer, and Director. The company holds eight ex-U.S. patent applications and one international patent application covering its Organicell product line and proprietary perinatal fluid processing techniques, and faces ongoing FDA regulatory requirements for its human cell, tissue, and cellular and tissue-based products.

Revenue model

Transactional sales of biologically derived perinatal tissue products (Organicell line) and topical aesthetic products acquired via BioLumina LLC. The company also acts as a sales representative for Exotropin LLC skin care products under an agreement entered August 2024.

Products and services

Organicell line of biologically derived perinatal tissue products, including the Zofin brand (trademark registration number 7,469,132, filing date July 13, 2020) and Organicell PPX (blood-derived exosomes for pain treatment). Topical aesthetic products and trademarks acquired through BioLumina LLC (acquired June 25, 2025). Skin care products distributed under the Exotropin sales representative agreement (entered August 2024).

Customers and end markets

End markets include aesthetic and medical regenerative applications. Customers face limited third-party payer reimbursement and require training on product use, per the 10-K filed January 29, 2026. No specific customer concentration data disclosed in the excerpts.

Value-chain role

Developer, processor, and distributor of perinatal-derived biologic products. Also acts as a downstream sales representative for third-party skin care formulators.

Geographic exposure

U.S.-based operations, trading on the OTCQB market. Patent applications filed in Mexico, Panama, and Canada for the Organicell product line.

Source: SEC 10-K, filed 2026-01-29

Industry: Biological Products, (No Diagnostic Substances) Peers: X4 Pharmaceuticals Inc Bolt Biotherapeutics Inc Curis Inc Senti Biosciences Inc Korro Bio Inc ImmuCell Corp Pyxis Oncology Inc SQZ Biotechnologies Co Surface Oncology, Inc.